Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029674 | 0.89 | MDM4 (0.48) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL3309050 | 0.86 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL29423449 | 0.86 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL29793991 | 0.86 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL2367138 | 0.86 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL24899366 | 0.86 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL31370735 | 0.86 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL25253964 | 0.85 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL24899321 | 0.85 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A | |
| SCHEMBL21219839 | 0.85 | MDM4 (0.52) | MDM4TP53MDM2CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12480950-B2 | AKT-specific capture agents, compositions, and methods of using and making | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250264471-A1 | AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | INDI MOLECULAR, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250130235-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2025-04-24 | — | — | US | disclosed |
| US-20230019342-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2023-01-19 | — | — | US | disclosed |
| US-11371994-B2 | Phosphorylated Akt-specific capture agents, compositions, and methods of using and making | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11371994-B2 | Phosphorylated Akt-specific capture agents, compositions, and methods of using and making | PIK3CA, PIK3CB, AKT3 | MDM4 1800/4885TP53 384/4885MDM2 2307/4885 |
| US-12480950-B2 | AKT-specific capture agents, compositions, and methods of using and making | PIK3CA, AKT3, AKT2 | MDM4 1442/4885TP53 240/4885MDM2 1303/4885 |
| US-20250130235-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | PIK3CA, PIK3CB, AKT3 | MDM4 1800/4885TP53 384/4885MDM2 2307/4885 |
| US-20230019342-A1 | PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | PIK3CA, PIK3CB, AKT3 | MDM4 1800/4885TP53 384/4885MDM2 2307/4885 |
| US-20250264471-A1 | AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | PIK3CA, AKT3, AKT2 | MDM4 1442/4885TP53 240/4885MDM2 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.